| Contract Development and Manufacturing Organization (CDMO) | Manufacturing generic pharmaceuticals including oral solids, liquids, injectables, and complex dosage forms. | Strong client relationships, large diversified product portfolio, state-of-the-art facilities in India. | B2B clients comprising Indian pharmaceutical companies and exporters. | Complex dosage forms and modified release tablets. | 660 | 53 | Revenue from manufacturing contracts with 300+ pharmaceutical clients, mostly long-term engagements. | Contract-based manufacturing revenue, mostly recurring and volume-driven. | Increasing client engagements, expanded product offerings, capacity utilization improvements. | |
| Domestic Branded Generics | Wide range of branded formulations marketed through extensive Indian distribution network. | Strong Indian distribution network and growing brand portfolio. | B2C patients and pharmacies throughout India with 6,000+ distributors and 2,20,000+ touchpoints. | High-demand branded medicines in chronic and acute therapies. | 230 | 19 | Sales via domestic pharmaceutical retail channels and distributor network. | Direct sales with competitive pricing. | Network expansion and growing product basket from 600+ to 750+ products. | Univentis Medicare Limited products |
| International Branded Generics | Branded generic medicines distributed in 60+ countries including regulated markets like UK and Canada. | International certifications, growing global footprint. | B2C patients in international markets and global pharmacies. | Regulated markets' branded products. | 156 | 13 | Sales through distributors and pharmacies in export markets. | Direct sales via distributors, expanding regulated market presence. | Regulatory approvals, geographic expansion, penetration into new markets. | |
| Sharon Bio-Medicine Limited (Acquired) | Formulation and API manufacturing adhering to global quality standards. | Complementary capabilities and increased scale post-acquisition. | B2B pharmaceutical clients seeking formulation and API products. | Formulations and API manufacturing units. | 197 | 16 | Product sales from formulations and API production. | Sales revenue from own manufactured products. | Synergy with Innova's platform, cost optimization and enhanced profitability post-acquisition. | |
